-
Je něco špatně v tomto záznamu ?
Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies
S. Luzzago, ML. Piccinelli, G. Marvaso, E. Laukhtina, N. Miura, VM. Schuettfort, K. Mori, A. Aydh, M. Ferro, FA. Mistretta, N. Fusco, G. Petralia, BA. Jereczek-Fossa, SF. Shariat, PI. Karakiewicz, O. de Cobelli, G. Musi
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- biopsie MeSH
- lidé MeSH
- nádory prostaty * patologie MeSH
- pozorné vyčkávání MeSH
- prostata * diagnostické zobrazování patologie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To test discontinuation rates during Active Surveillance (AS) in patients diagnosed with incidental prostate cancers (IPCa) vs. tumors diagnosed at prostate biopsies (BxPCa). METHODS: Retrospective single center analysis of 961 vs. 121 BxPCa vs. IPCa patients (2008-2020). Kaplan-Meier plots and multivariable Cox regression models tested four different outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading; (3) biopsy discontinuation due to ISUP GG upgrading or > 3 positive cores; (4) biopsy discontinuation or suspicious extraprostatic extension at surveillance mpMRI. Then, multivariable logistic regression models tested rates of clinically significant PCa (csPCa) (ISUP GG ≥ 3 or pT ≥ 3a or pN1) after radical prostatectomy (RP). RESULTS: Median time follow-up was 35 (19-64) months. IPCa patients were at lower risk of any-cause (3-year survival: 79.3 vs. 66%; HR: 0.5, p = 0.001) and biopsy/MRI AS discontinuation (3-year survival: 82.3 vs. 72.7%; HR: 0.5, p = 0.001), compared to BxPCa patients. Conversely, IPCa patients exhibited same rates of biopsy discontinuation and ISUP GG upgrading over time, relative to BxPCa. In multivariable logistic regression models, IPCa patients were associated with higher rates of csPCa at RP (OR: 1.4, p = 0.03), relative to their BxPCa counterparts. CONCLUSION: AS represents a safe management strategy for IPCa. Compared to BxPCa, IPCa patients are less prone to experience any-cause and biopsy/MRI AS discontinuation. However, the two mentioned groups present similar rates of biopsy discontinuation and ISUP GG upgrading over time. In consequence, tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.
Department of Oncology and Haemato Oncology Università degli Studi di Milano 20122 Milan Italy
Department of Pathology IEO European Institute of Oncology IRCCS Via Ripamonti 435 Milan Italy
Department of Radiotherapy IEO European Institute of Oncology IRCCS Via Ripamonti 435 Milan Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Ehime University Graduate School of Medicine Ehime Japan
Department of Urology IEO European Institute of Oncology IRCCS Via Ripamonti 435 20141 Milan Italy
Department of Urology King Faisal Medical City Abha Saudi Arabia
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
European Association of Urology Research Foundation Arnhem The Netherlands
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011231
- 003
- CZ-PrNML
- 005
- 20220506130223.0
- 007
- ta
- 008
- 220425s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-021-03864-6 $2 doi
- 035 __
- $a (PubMed)34687344
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Luzzago, Stefano $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy. stefanoluzzago@gmail.com $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy. stefanoluzzago@gmail.com $1 https://orcid.org/0000000293731413
- 245 10
- $a Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies / $c S. Luzzago, ML. Piccinelli, G. Marvaso, E. Laukhtina, N. Miura, VM. Schuettfort, K. Mori, A. Aydh, M. Ferro, FA. Mistretta, N. Fusco, G. Petralia, BA. Jereczek-Fossa, SF. Shariat, PI. Karakiewicz, O. de Cobelli, G. Musi
- 520 9_
- $a PURPOSE: To test discontinuation rates during Active Surveillance (AS) in patients diagnosed with incidental prostate cancers (IPCa) vs. tumors diagnosed at prostate biopsies (BxPCa). METHODS: Retrospective single center analysis of 961 vs. 121 BxPCa vs. IPCa patients (2008-2020). Kaplan-Meier plots and multivariable Cox regression models tested four different outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading; (3) biopsy discontinuation due to ISUP GG upgrading or > 3 positive cores; (4) biopsy discontinuation or suspicious extraprostatic extension at surveillance mpMRI. Then, multivariable logistic regression models tested rates of clinically significant PCa (csPCa) (ISUP GG ≥ 3 or pT ≥ 3a or pN1) after radical prostatectomy (RP). RESULTS: Median time follow-up was 35 (19-64) months. IPCa patients were at lower risk of any-cause (3-year survival: 79.3 vs. 66%; HR: 0.5, p = 0.001) and biopsy/MRI AS discontinuation (3-year survival: 82.3 vs. 72.7%; HR: 0.5, p = 0.001), compared to BxPCa patients. Conversely, IPCa patients exhibited same rates of biopsy discontinuation and ISUP GG upgrading over time, relative to BxPCa. In multivariable logistic regression models, IPCa patients were associated with higher rates of csPCa at RP (OR: 1.4, p = 0.03), relative to their BxPCa counterparts. CONCLUSION: AS represents a safe management strategy for IPCa. Compared to BxPCa, IPCa patients are less prone to experience any-cause and biopsy/MRI AS discontinuation. However, the two mentioned groups present similar rates of biopsy discontinuation and ISUP GG upgrading over time. In consequence, tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a prostata $x diagnostické zobrazování $x patologie $7 D011467
- 650 12
- $a nádory prostaty $x patologie $7 D011471
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a pozorné vyčkávání $7 D057832
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Piccinelli, Mattia Luca $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy $u Università degli Studi di Milano, Milan, Italy
- 700 1_
- $a Marvaso, Giulia $u Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy
- 700 1_
- $a Laukhtina, Ekaterina $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Aydh, Abdulmajeed $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Faisal Medical City, Abha, Saudi Arabia
- 700 1_
- $a Ferro, Matteo $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy
- 700 1_
- $a Mistretta, Francesco A $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy
- 700 1_
- $a Fusco, Nicola $u Department of Pathology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
- 700 1_
- $a Petralia, Giuseppe $u Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
- 700 1_
- $a Jereczek-Fossa, Barbara A $u Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Research Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u European Association of Urology Research Foundation, Arnhem, The Netherlands
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
- 700 1_
- $a de Cobelli, Ottavio $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
- 700 1_
- $a Musi, Gennaro $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 40, č. 2 (2022), s. 443-451
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34687344 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130215 $b ABA008
- 999 __
- $a ok $b bmc $g 1789035 $s 1162429
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 40 $c 2 $d 443-451 $e 20211023 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20220425
